- Dr. Saloni Wagh, Director, Supriya Lifescience
“With its emphasis on progress through targeted support for Garib (the poor), Mahilayen (women), Yuva (the youth), and Annadata (farmers), this budget represents a vital step towards a Vikasit Bharat. Employment, skill development, MSME growth (which is essential to GDP and exports), and middle-class uplift are important areas of attention.
A noteworthy development that could have a significant positive impact on cancer patients and the pharmaceutical industry is the complete exemption of basic customs duties from three cancer treatment medications. India is expected to be the world leader in medicines, with ₹2,143 crore allocated under the Production Linked Incentive (PLI) plan. By 2030, the country’s pharmaceutical sector is expected to reach USD 130 billion. These actions are essential to reaching our three-year target of $5 trillion and our 2030 target of $7 trillion in GDP.
Furthermore, the Prime Minister’s plan includes significant funding (₹1.48 lakh crore for education and ₹2 lakh crore for employment and skill development) aimed at promoting job creation. It is also laudable that there is a greater focus on women’s workforce engagement through skill-specific skill-building programs and hostels. It is anticipated that these activities would produce a competent workforce that is essential to the precision and innovation industries.
Prioritizing innovation, research and development, and education also helps the budget progress both the public and private sectors. The government’s investment in these fields seeks to advance knowledge, improve the standard of education, and produce skilled labor. This focus will advance India’s manufacturing and technology industries and establish the nation as a significant hub for global manufacturing.
Supriya Lifescience Ltd
Supriya Lifescience Ltd., a world-renowned producer of active medicinal ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The facility’s headquarters are in Mumbai, India, and it is situated in Khed, District Ratnagiri.
Supriya Lifescience Ltd. has a well-established presence in API Manufacturing with focus in products of various therapeutic segments like – Antihistamine, Anti-Allergics, Vitamins, Anaesthetics, Anti- Asthmatics etc.
Backed by strong R&D, 14 active USDMFs, 8 active CEPs & Worldwide compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA). Core business is driven by Ethical values and EHS standards. The company’s focus is to develop APIs and Intermediates for both Innovators, Generic companies and we also partner exclusively as CMO.
The company was founded by Dr. Satish Wagh, a first-generation entrepreneur and technocrat. Armed with technical knowledge, business acumen and an extensive experience of more than 35 years in the pharmaceutical industry, he has been instrumental for what Supriya Lifescience is today.
